Senior Scientist / Scientist – Radiochemistry and Quality Control
Senior Scientist / Scientist in Radiochemistry – an exciting opportunity to contribute to the development of alpha-emitting radiopharmaceuticals in a dynamic and growing biotech company
Oncoinvent is looking for a Senior Scientist / Scientist in Radiochemistry to strengthen the Quality Control team at the manufacturing facility in Oslo. This role offers an exciting opportunity to contribute to the development of alpha-emitting radiopharmaceuticals in a dynamic and growing biotech company.
The successful candidate will, together with the Quality Control team, be responsible for radiochemical quality control of raw materials, drug substance (Ra-224) and drug product (Radspherin®).
This position requires work with radioactive materials. A successful candidate is therefore expected to comply with radiation protection and other health and safety procedures during laboratory- and production scale experiments, and GMP production activities.
Key responsibilities
- Develop and optimize radiochemical and chemical analytical methods for raw materials, intermediates and finished product
- Lead or take part in validating radiochemical analytical methods
- Conduct chemical and physical release testing of raw materials, intermediates, finished product and stability samples
- Contribute to the development of material and product specifications.
- Investigate deviations and ensure timely closure of records
- Collaborate with QC, QA and Production to resolve OOS, unexpected results and analytical issues
- Maintain, troubleshoot, and perform periodic audits on analytical instruments as needed
- Record, review and report analytical results in accordance with established procedures
- Prepare regulatory documents and contribute to inspection readiness
- Track progress against project plans, generate regular status updates, and communicate progress and issues
- Coordinate and lead writing of SOPs, policies, and other controlled documents.
- Procurement and qualification of analytical instruments
- Contribute to internal audits of contract manufacturers/laboratories
- Follow up with Contract Research Organization and ensure good communication and collaboration
- Support technology transfer of analytical test methods to secondary manufacturing sites
Qualifications and experience
The holder of the QC Senior Scientist or Scientist position should have the following documented qualifications and experience:
- M.Sc./ Ph.D. in radiochemistry or equivalent
- Strong knowledge in radiochemistry principles.
- Preferably 5-10 years of hands-on experience in method development and validation, ideally including radiochemical methods.
- Experience with radiation protection and safe handling of radioactive materials is a strong advantage.
- Knowledge of FDA, EMA, ICH, USP, and EP guidelines and regulations relevant to quality control.
- Experience from technology transfer of analytical methods is beneficial.
Location
The holder of this position will be based in Nydalen, at Oncoinvent Solutions AS, Gullhaugveien 7, 0484 Oslo. The position will report to the Head of Quality Control. The main part of the work will take place during normal working hours, but evening work and work on national holidays might occasionally be necessary for quality control of intermediate and final products.
Application
- Application deadline: We are reviewing candidates on a rolling basis
- Please submit your application with a motivational letter stating “why Oncoinvent” and what you can contribute to the position as well as an updated CV to HR@oncoinvent.com
- Applications without motivational letter and CV will not be reviewed further
- For questions about the position, please send us an email at HR@oncoinvent.com with your contact details and we will get back to you as soon as possible
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo Stock Exchange.
